Telehealth platform Mochi Health announced new pricing and a lab‑testing service aimed at making GLP‑1 weight‑loss treatments more affordable and medically supervised. The changes target patients who seek compounded semaglutide or tirzepatide but are concerned about cost and ongoing health monitoring.
New dose‑based pricing
Under the revised model, compounded semaglutide starts at $60 per month and compounded tirzepatide at $90 per month. Prices are tied to dosage levels, so patients beginning treatment on lower introductory doses pay less, with no dose costing more than the previous pricing structure.
New users enroll with a live 30‑minute virtual appointment with a licensed healthcare provider. Membership plans begin at $39 for the first month and include unlimited provider visits, direct messaging, and access to medical professionals. Medication costs are billed separately from the membership fee.
Mochi Labs: integrated blood testing
Alongside the pricing update, Mochi Health launched Mochi Labs, allowing patients to order and manage blood work through the same platform. Users can request tests via the portal, visit a participating laboratory, and receive results directly in their account.
The core health panel starts at $26 and includes cholesterol, hemoglobin A1C, thyroid screening, and comprehensive metabolic testing. Additional panels cover GLP‑1 monitoring, women’s health, men’s health, and broader health assessments. Providers can use these results to track metabolic health, thyroid function, and nutritional markers throughout treatment and adjust therapy as needed.
Why the changes matter
As GLP‑1 medications grow in popularity for weight management, many patients look for options that balance affordability with clinical oversight. Lower entry‑level pricing may broaden access for those beginning their weight‑loss journey, while integrated lab testing offers insight into how treatment affects overall health.
Mochi Health notes that the laboratory service is available in most states, though it is not currently offered in New York, New Jersey, Rhode Island, or Hawaii. Compounded semaglutide and tirzepatide remain the company’s primary treatment offerings.
Note: Compounded semaglutide and compounded tirzepatide are not FDA‑approved products. Brand‑name GLP‑1 medications may be referenced for context but are not substitutes for compounded medications.
Original reporting: Las Cruces Sun News (HLL/CB) — read the source article.
